Dashboard/Countries/🇪🇬 Egypt
High — 2 signed contracts with product-overlap risk

🇪🇬 Egypt

2 signed distribution agreements (5 Stars For Trade And Import + Elfath). Sphere-of-influence overlap risk between the two: both cover overlapping vet products and Article 6 (Competing Products) covenant could be breached in either. Elfath is the WORST scoring contract in MENA (triple-headed defect at Art. 33).

Country profile GAP — Egypt not in country notes

Egypt — regulatory context

GAP. Egypt is not yet in the counterparty-country-notes.md reference (which currently covers UAE, Tunisia, Iraq, Jordan, Lebanon, Algeria, Morocco, etc., but not Egypt). The data below is sourced from the deep reviews of the 5stars and Elfath contracts. Verify with Egyptian local counsel before relying.

Vet drug authority
EDA (Egyptian Drug Authority), formerly GADA / CAPA. Vet pharmaceuticals registered under the Vet Pharmaceutical Department.
Commercial agency law
Law 120/1982 on Commercial Agency. Registration with GAFI (General Authority for Investment and Free Zones) — distinction between agent (with statutory compensation) and distributor (own-account, no compensation) is important. Non-registration with GAFI keeps the relationship as a distribution, not agency.
FX rules
Central Bank of Egypt — periodic FX shortages; multi-tier FX system has applied in recent years. Repatriation via authorised dealer; documentation heavy.
Stamp duty
Bea Meterai equivalent — verify Egyptian stamp tax rules with local counsel.
Multi-distributor permissibility
CONDITIONAL (GAP — verify) If registered as agent under Law 120/1982, exclusivity attaches and a second distributor would trigger statutory compensation. If structured as distributor (own-account, no GAFI agency registration), multi-distributor permitted.
Voidance risks
  • Language law: Arabic typically required for state-court enforcement; foreign-language contracts need certified Arabic translation.
  • Law 120/1982 trigger: GAFI agency registration triggers statutory compensation on termination — non-registration keeps the relationship as own-account distribution.
  • Sharia compatibility: Egyptian Civil Code Sharia-influenced; late-payment interest can be recharacterized.
  • Formalities: Egypt is Hague Apostille Convention member.
  • Article 33 dual-law + dual-forum defect in the Elfath contract is unique in the portfolio — will paralyse any dispute 12-24 months.
GAPS to verify with Egyptian local counsel
(i) current EDA registration timelines and fees; (ii) Law 120/1982 agency vs distribution boundary; (iii) Egyptian stamp tax application to foreign distribution agreements; (iv) GAFI non-registration confirmation procedure.
Signed contracts in this country

5 Stars For Trade And Import

Counterparty
5 Stars For Trade And Import
Effective
18 November 2024
Term
5 years — until ~18 November 2029
Score / grade
69 / 100C
Review status
Deep review on the October 2024 DRAFT — re-review against signed 18 Nov 2024 version pending
Annual cliff
31 October each year

Top 3 issues

  1. Standard dual BANI/SIAC defect (Art. 34.2).
  2. MA holder economics — counterparty + JAPFA pays half registration.
  3. Missing sanctions exit.

Authorized Products (current LOA)

Source: Schedule A. Egyptian EDA (Egyptian Drug Authority) MA economics complicated by counterparty + JAPFA paying half registration.

#ProductStrainDose
1Vaksimune NDLSND Lasota1000 ds
2Vaksimune ND Clone IBND Clone + IB1000 ds
3Vaksimune IBD M+IBD intermediate-plus1000 ds
4Vaksimune IBD LIBD live1000 ds
5Vaksimune IBH DuoIBH 8b + I11000 ds
6Vaksimune Coryza LECoryza multi-strain1000 ds
7Vaksimune ND L InaktifND inactivated1000 ds
8Vaksimune AI Multi H5+H9AI H5+H91000 ds

Sphere-of-Influence overlap with Elfath (Egypt's other distributor) on ~5 SKUs — Article 6 (Competing Products) covenant could be breached in either contract.

Elfath — re-engagement after 2022 termination

Counterparty
Elfath
Status
Fresh engagement after 21 Jan 2022 termination by Vaksindo of the prior 2013/2017 contract for missed sales targets
Effective
2024
Term end
1 January 2029
Score / grade
55 / 100C
Template
Standard Vaksindo, Art. 33 numbering
Termination history
Original 2013 contract + 2017 annex terminated 21 Jan 2022 by Vaksindo for missed sales targets. Current 2024 contract is a re-engagement of a counterparty just terminated for cause — high-risk re-engagement.
Deep review
Open the deep-review dashboard ›

Top 3 issues

  1. DUAL law + DUAL forum at Art. 33 — uniquely bad in portfolio; will paralyse any dispute 12-24 months.
  2. Articles 4.2/4.3 directly contradict on EDA MA ownership.
  3. Re-engagement of counterparty just terminated for cause in Jan 2022.

Authorized Products (current LOA)

Source: Schedule A. Overlaps with Egypt 5Stars on ~5 SKUs — Sphere-of-Influence side-letter required.

#ProductStrainDose
1Vaksimune NDLSND Lasota1000 ds
2Vaksimune ND CloneND Clone1000 ds
3Vaksimune ND Clone IBND Clone + IB1000 ds
4Vaksimune IBD LIBD live1000 ds
5Vaksimune IBD M+IBD intermediate-plus1000 ds
6Vaksimune PoxFowlpox1000 ds
7Vaksimune Coryza LECoryza multi-strain1000 ds
8Vaksimune ND L InaktifND inactivated1000 ds
9Vaksimune NDL Multi IBPlusND-L + IB combination1000 ds
Country watch items

Elfath — WORST IN PORTFOLIO

Severity: CRITICAL.

Triple-headed defect (dual law + dual forum at Art. 33) + Termination of Agreement & Annexes (1).pdf in folder.

Action: Deep review in progress 2026-05-11; verify termination doc; reserve Law 120/1982 compensation. Note: the Termination doc is the 2021 termination of the prior 2013/2017 contract — NOT the current 2024 contract.

Egypt 5stars vs Egypt Elfath product overlap reconciliation

Priority: HIGH. Deadline: Before next 31 October cliff for either contract.

Both signed; both cover overlapping vet products; Article 6 (Competing Products) covenant could be breached in either. Reconcile both Schedule A's at SKU level; draft Sphere-of-Influence side-letter splitting Egyptian channels (e.g., Elfath = government tender / institutional; 5stars = private vet clinics).

Suggested actions ranked by urgency
Elfath — Side-letters & amendments
  1. Article 33 fix (single Indonesian law + SIAC Singapore + 3 arbitrators + English + CISG excluded + KUHPerdata 1266/1267 waiver).
  2. Articles 4.2/4.3 MA reconciliation (JAPFA owns the Egypt EDA MA; Elfath as bailee during term).
  3. New Article 22 + 30.1 — Egypt Law 120/1982 distributor-not-agent declaration + GAFI non-registration confirmation.
  4. Sphere-of-Influence side-letter de-conflicting with Egypt 5stars (overlapping products may breach Article 6 in either contract).
  5. Articles 4.5/23.4 USD 49,118 reimbursement carve-out clarification.
  6. Affix Bea Meterai stamp duty on Indonesian-side execution copies.
  7. Execute Bahasa Indonesia parallel version (UU 24/2009 / Nine AM precedent).
  8. Verify EDA registration status for all 13 Schedule A products + LoA-listed extras.
  9. Tighten Article 7 minimums consequence ladder (post-2022-termination history risk).
5 Stars — restructure + sanctions exit
  1. Restructure Art. 4.2 MA economics (counterparty pays + escrowed PoA).
  2. Move Art. 21.4 to 12-month liability cap.
  3. Strip "marketing representative" language (Arts. 17.5 / 24.5).
  4. Add KUHPerdata 1266/1267 waiver.
  5. Add CISG express exclusion.
  6. Add sanctions exit clause.
  7. Complete Schedule A with quantified minimums (was empty in Oct 2024 draft).
  8. Re-review against signed 18 Nov 2024 version.
Drafts in progress
☑

No drafts in progress for Egypt

Sphere-of-Influence side-letter between 5stars and Elfath is the next likely draft session.

Marketing agreements
☰

No marketing agreements indexed